deferiprone has been researched along with Cardiovascular Abnormalities in 1 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Cardiovascular Abnormalities: Congenital, inherited, or acquired anomalies of the CARDIOVASCULAR SYSTEM, including the HEART and BLOOD VESSELS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we used deferiprone (DFP) as an iron chelating agent in TI patients receiving intermittent blood transfusion who are asymptomatic for cardiovascular disease in order to evaluate the effectiveness in iron overload and reduce the possibility of cardiovascular complications." | 9.15 | Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients. ( Akrawinthawong, K; Chaowalit, N; Chatuparisuth, T; Siritanaratkul, N, 2011) |
| " Here, we used deferiprone (DFP) as an iron chelating agent in TI patients receiving intermittent blood transfusion who are asymptomatic for cardiovascular disease in order to evaluate the effectiveness in iron overload and reduce the possibility of cardiovascular complications." | 5.15 | Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients. ( Akrawinthawong, K; Chaowalit, N; Chatuparisuth, T; Siritanaratkul, N, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akrawinthawong, K | 1 |
| Chaowalit, N | 1 |
| Chatuparisuth, T | 1 |
| Siritanaratkul, N | 1 |
1 trial available for deferiprone and Cardiovascular Abnormalities
| Article | Year |
|---|---|
Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients.
Topics: Adolescent; Adult; beta-Thalassemia; Cardiovascular Abnormalities; Deferiprone; Echocardiography, Do | 2011 |